X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12524) 12524
Book Chapter (170) 170
Publication (31) 31
Dissertation (19) 19
Conference Proceeding (13) 13
Magazine Article (8) 8
Book Review (3) 3
Book / eBook (2) 2
Journal / eJournal (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7557) 7557
antiplatelet therapy (5495) 5495
male (4032) 4032
cardiac & cardiovascular systems (3885) 3885
clopidogrel (3775) 3775
female (3716) 3716
aspirin (3595) 3595
aged (3028) 3028
platelet aggregation inhibitors - therapeutic use (2982) 2982
middle aged (2963) 2963
percutaneous coronary intervention (2460) 2460
treatment outcome (2086) 2086
ticlopidine - analogs & derivatives (2066) 2066
dual antiplatelet therapy (2034) 2034
risk factors (2028) 2028
peripheral vascular disease (1851) 1851
antiplatelet (1812) 1812
thrombosis (1760) 1760
stroke (1575) 1575
platelet aggregation inhibitors - adverse effects (1549) 1549
platelet aggregation inhibitors - administration & dosage (1478) 1478
pharmacology & pharmacy (1473) 1473
risk (1420) 1420
myocardial-infarction (1408) 1408
hematology (1338) 1338
acute coronary syndromes (1328) 1328
anticoagulants (1313) 1313
ticlopidine - therapeutic use (1273) 1273
stents (1257) 1257
aspirin - therapeutic use (1230) 1230
drug therapy, combination (1169) 1169
prevention (1153) 1153
surgery (1142) 1142
acute coronary syndrome (1097) 1097
mortality (1090) 1090
abridged index medicus (1058) 1058
therapy (1051) 1051
cardiology (1033) 1033
time factors (1028) 1028
adult (1013) 1013
aged, 80 and over (1003) 1003
antiplatelet agents (1001) 1001
care and treatment (990) 990
bleeding (928) 928
drug-eluting stents (909) 909
medicine, general & internal (900) 900
retrospective studies (894) 894
platelet aggregation - drug effects (889) 889
acute myocardial-infarction (885) 885
ticagrelor (879) 879
drug therapy (877) 877
platelet aggregation inhibitors - pharmacology (876) 876
prasugrel (872) 872
coronary heart disease (866) 866
management (864) 864
myocardial infarction (851) 851
blood platelets (850) 850
cardiovascular (841) 841
prospective studies (831) 831
animals (822) 822
analysis (811) 811
anticoagulation (811) 811
warfarin (807) 807
medicine & public health (802) 802
outcomes (794) 794
ticlopidine - administration & dosage (783) 783
clinical neurology (779) 779
cardiovascular disease (778) 778
heart attacks (769) 769
hemorrhage - chemically induced (765) 765
anticoagulants - therapeutic use (762) 762
intervention (762) 762
aspirin - administration & dosage (761) 761
risk assessment (742) 742
cardiac patients (737) 737
double-blind (734) 734
cardiovascular diseases (709) 709
stent (701) 701
blood platelets - drug effects (696) 696
coronary artery disease (687) 687
secondary prevention (684) 684
patients (682) 682
platelets (679) 679
trial (670) 670
aggregation (664) 664
atrial fibrillation (661) 661
stent thrombosis (637) 637
ticlopidine - adverse effects (628) 628
implantation (624) 624
aspirin - adverse effects (618) 618
artery-disease (595) 595
follow-up studies (586) 586
angioplasty (579) 579
atrial-fibrillation (571) 571
acute coronary syndrome - drug therapy (560) 560
antithrombotic therapy (560) 560
elevation myocardial-infarction (550) 550
internal medicine (549) 549
disease (546) 546
metaanalysis (543) 543
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12087) 12087
German (263) 263
Japanese (238) 238
French (164) 164
Russian (121) 121
Spanish (117) 117
Polish (39) 39
Portuguese (33) 33
Czech (23) 23
Korean (17) 17
Italian (13) 13
Turkish (10) 10
Chinese (8) 8
Hungarian (3) 3
Norwegian (3) 3
Slovak (2) 2
Slovenian (2) 2
Arabic (1) 1
Croatian (1) 1
Dutch (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e669S - e690S
Journal Article
Clinical research in cardiology, ISSN 1861-0684, 2019, Volume 109, Issue 1, pp. 128 - 130
... therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy? Bernhard Wernly1 · Michael Lichtenauer1 · David Erlinge2 · Christian Jung3... 
PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTIPLATELET THERAPY | Therapy | Fibrillation | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
.... The risk of bleeding was lower with dabigatran therapy; prevention of thromboembolic events was similar with the two strategies. 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2015, Volume 65, Issue 16, pp. 1619 - 1629
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2015, Volume 65, Issue 8, pp. 777 - 786
Background The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent... 
double antiplatelet duration | percutaneous coronary angioplasty | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | THROMBOSIS | BARE-METAL STENTS | FOLLOW-UP | RISK | PERCUTANEOUS CORONARY INTERVENTION | IMPACT | POOLED ANALYSIS | CLINICAL-OUTCOMES | PLATELET REACTIVITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Postoperative Complications - prevention & control | Male | Hemorrhage - prevention & control | Aspirin - administration & dosage | Drug-Eluting Stents - adverse effects | Middle East | Early Termination of Clinical Trials | Coronary Restenosis - diagnosis | Coronary Artery Disease - physiopathology | Time Factors | Aspirin - adverse effects | Percutaneous Coronary Intervention - methods | Hemorrhage - etiology | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Everolimus | Coronary Restenosis - etiology | Platelet Aggregation Inhibitors - adverse effects | Coronary Vessels - pathology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Europe | Coronary Restenosis - prevention & control | Treatment Outcome | Coronary Artery Disease - mortality | Postoperative Complications - diagnosis | Ticlopidine - analogs & derivatives | Coronary Artery Disease - therapy | Coronary Artery Disease - diagnosis | Coronary Vessels - surgery | Aged | Percutaneous Coronary Intervention - adverse effects | Aspirin
Journal Article
Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 8, p. CD003085
Background: Around 30% of people who are admitted to hospital with aneurysmal subarachnoid haemorrhage (SAH) will rebleed in the initial month after the... 
Pharmacology (medical) | Radiological therapy versus surgical therapy | Recurrence | Brain Ischemia | Stroke | Radiological therapy | Surgical therapy | Endovascular Procedures | Intracranial Aneurysm | Treatment Outcome | Secondary Prevention | Embolization, Therapeutic | Subarachnoid haemorrhage | Aneurysm, Ruptured | Randomized Controlled Trials as Topic | Neurosurgical Procedures | Neurology | Treatment | Subarachnoid Hemorrhage | Heart & circulation | Medicine General & Introductory Medical Sciences | Stents | Postoperative Complications | Surgical therapy versus radiological therapy | MORTALITY | Aneurysm, Ruptured [surgery; therapy] | Humans | FOLLOW-UP | Subarachnoid Hemorrhage [surgery; therapy] | ANTIPLATELET THERAPY | CEREBRAL ANEURYSMS | REGION | TRIAL | MEDICINE, GENERAL & INTERNAL | Neurosurgical Procedures [methods] | Intracranial Aneurysm [surgery; therapy] | RUPTURED INTRACRANIAL ANEURYSMS | OUTCOMES | ISAT | Brain Ischemia - epidemiology | Neurosurgical Procedures - adverse effects | Postoperative Complications - etiology | Aneurysm, Ruptured - mortality | Subarachnoid Hemorrhage - therapy | Intracranial Aneurysm - mortality | Postoperative Complications - epidemiology | Brain Ischemia - etiology | Secondary Prevention - methods | Intracranial Aneurysm - surgery | Endovascular Procedures - methods | Intracranial Aneurysm - therapy | Aneurysm, Ruptured - therapy | Subarachnoid Hemorrhage - mortality | Aneurysm, Ruptured - surgery | Neurosurgical Procedures - methods | Subarachnoid Hemorrhage - surgery
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 10/2016, Volume 134, Issue 14, pp. 989 - 998
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e637S - e668S
Background: This guideline focuses on long-term administration of antithrombotic drugs designed for primary and secondary prevention of cardiovascular disease, including two new antiplatelet therapies. Methods... 
LONG-TERM | CHRONIC HEART-FAILURE | COST-EFFECTIVENESS | LEFT-VENTRICULAR THROMBUS | LOW-DOSE ASPIRIN | DUAL ANTIPLATELET THERAPY | ANTERIOR MYOCARDIAL-INFARCTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | RANDOMIZED-TRIAL | ACUTE CORONARY SYNDROMES | CRITICAL CARE MEDICINE | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Long-Term Care | Secondary Prevention | Angioplasty, Balloon, Coronary | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Societies, Medical | Coronary Disease - complications | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - blood | Thrombosis - blood | Thrombosis - prevention & control | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Platelet Aggregation Inhibitors - adverse effects | Coronary Disease - blood | Risk Factors | Myocardial Ischemia - blood | Combined Modality Therapy | Evidence-Based Medicine | Myocardial Ischemia - drug therapy | Myocardial Ischemia - complications | Coronary Disease - drug therapy | Aged | Thrombosis - drug therapy | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2018, Volume 72, Issue 23, pp. 2886 - 2903
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 16, pp. 1509 - 1524
Journal Article